BioSpace News Archive

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the first quarter ended March 31, 2022.

Exicure, Inc. reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.

Aytu BioPharma, Inc., a pharmaceutical company focused on developing and commercializing novel therapeutics, reported financial results for its fiscal 2022 third quarter, ended March 31, 2022 and outlined its key strategic priorities.

Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.

Celularity Inc. announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.

INVO Bioscience, Inc. announced it has entered an exclusive distribution agreement with Onesky Holdings Limited for Mainland China.

PolarityTE, Inc. announced that the Company will effectuate a 1-for-25 reverse stock split of the Company’s issued and outstanding common stock, which will be effective under Delaware law at 4:15 p.m. Eastern Time on Monday, May 16, 2022.

La Jolla Pharmaceutical Company announced financial results for the three months ended March 31, 2022 and highlighted corporate progress.

Viatris Inc. published its 2021 Sustainability Report, outlining the company’s 2021 achievements and progress across key areas including Access and Global Health, Employees, Environmental Stewardship and Community Engagement and including details on Viatris’ continued efforts to support employees and their families while maintaining a stable supply of medicines during the ongoing COVID-19 pandemic.

Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma.